Atox Bio is a critical care immunotherapy company focusing on acute, life-threatening, conditions. It develops Reltecimod, an immunomodulator that is designed to enhance resolution of organ failure in conditions associated with severe, acute inflammation such as Necrotizing Soft Tissue Infection and sepsis.